Quantcast
Last updated on April 18, 2014 at 5:48 EDT

Latest Elcelyx Therapeutics Stories

2013-09-17 08:31:27

SAN DIEGO, Sept. 17, 2013 /PRNewswire/ -- Elcelyx Therapeutics today announced that clinical advisor, John Buse, M.D., Ph.D., will present clinical data for NewMet(TM), a delayed-release formulation of generic metformin, in an oral presentation at the 49th Annual European Association for the Study of Diabetes (EASD) Meeting in Barcelona, Spain. Dr. Buse, Professor of Medicine and Director, Diabetes Care Center, Chief, Division of Endocrinology, Executive Associate Dean for Clinical Research...

2013-06-14 16:25:07

SAN DIEGO, June 14, 2013 /PRNewswire/ -- Elcelyx Therapeutics today announced that the company and principal investigator Ralph A. DeFronzo, M.D. will present posters related to NewMet(TM), a delayed-release formulation of generic metformin, at the 73(rd) Scientific Sessions of the American Diabetes Association in Chicago, IL. Dr. DeFronzo, Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Audie L. Murphy Memorial Veterans...

2013-05-20 08:26:55

SAN DIEGO, May 20, 2013 /PRNewswire/ -- Enrollment of patients with Type 2 diabetes is underway in Elcelyx Therapeutics' Phase 2b dose-finding clinical trial of product candidate NewMet(TM), a delayed-release formulation of generic metformin, the foundational treatment for Type 2 diabetes. Elcelyx expects to complete enrollment of 240 patients in the multicenter U.S. program in June. Results of the trial's primary endpoint of change in fasting plasma glucose are expected in late summer, and...

2013-02-14 08:28:54

SAN DIEGO, Feb. 14, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today the closing of a $20 million Series C financing to fund development of product candidates NewMet(TM) for Type 2 diabetes and Lovidia(TM), an over-the-counter weight loss product. The financing was led by GSM Fund LLC, a fund dedicated to this single investment and managed by Rick Barry, who has been elected to the Elcelyx Board of Directors. All previous investors also participated in the round, including...

2012-08-13 02:25:43

SAN DIEGO, Aug. 13, 2012 /PRNewswire/ -- Elcelyx Therapeutics announced today that Mark Wiggins has joined the company as Senior Vice President of Business Development and Ginger Graham has been elected to the Board of Directors. Elcelyx is developing ultra-safe first-in-class approaches to weight management and obesity-related metabolic disorders. "In two short years, Elcelyx has amassed proof of concept and efficacy data for two product candidates for weight loss, Type 2 diabetes and other...

2012-08-13 02:25:42

SAN DIEGO, Aug. 13, 2012 /PRNewswire/ -- Elcelyx Therapeutics announced today that it has secured $4 million of a $7 million extension of its Series B private equity financing. Existing investors Morgenthaler Ventures, Kleiner Perkins Caufield & Byers and Technology Partners all participated in the extension. Founded in 2010, Elcelyx has raised a total of $20 million, including the $4 million, and advanced two product candidates for weight loss and the treatment of diabetes and obesity...